Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, randomised, placebo-controlled study of EDP2939 in healthyvolunteers and participants with moderate plaque psoriasis

Next Previous
X
Search
Trial Profile

A Phase 1/2, randomised, placebo-controlled study of EDP2939 in healthyvolunteers and participants with moderate plaque psoriasis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EDP 2939 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Evelo Biosciences

    • Most Recent Events

    • 17 Oct 2023 according to an Evelo Biosciences media release, the company is continuing to gather and analyze the study data. Ongoing analysis of the secondary endpoints continues.
    • 17 Oct 2023 Topline results from phase 2 study presented in an Evelo Biosciences Media Release.
    • 17 Oct 2023 Primary endpoint (Proportion of patients who achieve an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI-50 response) after 16 weeks of daily oral administration of EDP2939 or placebo.) has not been met, according to an Evelo Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top